Dengue vaccine: WHO position paper, July 2016 – recommendations

Vaccine

Volumn 35, Issue 9, 2017, Pages 1200-1201

  World Health Organization, ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

CYD TDV; Dengue; Dengue vaccine; Dengue virus; Dengvaxia ; Recombinant tetravalent dengue vaccine; WHO vaccine position paper

Indexed keywords

DENGUE VACCINE;

DRUG INDICATION; DRUG MONITORING; HEALTH CARE POLICY; HUMAN; IMMUNE DEFICIENCY; NOTE; PRIORITY JOURNAL; SEROPREVALENCE; SEVERE DENGUE; VACCINATION; WORLD HEALTH ORGANIZATION; DENGUE; FEMALE; MALE; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH;

DENGUE; DENGUE VACCINES; FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; MALE; PRACTICE GUIDELINES AS TOPIC; PUBLIC HEALTH; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 85011600837     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.10.070     Document Type: Note

References (7)

1. [1] Dengue vaccine: WHO position paper – July 2016. Weekly epidemiological record 2016; 91(30): 349–64.
2. [2] World Health Organization. Global vaccine safety blueprint. Available at http://extranet.who.int/iris/restricted/bitstream/10665/70919/1/WHO_IVB_12.07_eng.pdf?ua=1. [accessed October 2016].
3. [3] For highly endemic settings (e.g. seroprevalence at 9 years of age of approximately 90% or greater), modelling predicts vaccination at 9 years of age will maximize programme impact. In settings where seroprevalence at 9 years of age is between 50% and 90%, higher impact may be achieved with vaccination at 11–14 years of age.
4. [4] Flasche S, et al., Comparative modelling of dengue vaccine public health impact. Available at http://www.who.int/immunization/sage/meetings/2016/april/2_CMDVI_Report_FINAL.pdf. [accessed October 2016].
5. [5] “Administration of multiple injectable vaccines in a single visit” in meeting of the strategic advisory group of experts on immunization, April 2015: conclusions and recommendations. Weekly Epidemiological Record 2015; 90(22): 261–78.
6. [6] Background paper on dengue vaccines. World Health Organization, Geneva, Switzerland; 2016. Available at http://www.who.int/entity/immunization/sage/meetings/2016/april/1_Background_Paper_Dengue_Vaccines_2016_03_17.pdf.
7. [7] Plennevaux, E., et al. Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: utility for efficacy evaluation and impact of future vaccine introduction. Vaccine 34:24 (2016), 2707–2712.